GlassScriptPhysician profile
Azra Velic
NPI 1023480100
$4,009.24
in general payments reported to CMS, 2019-2025
29 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,133 · 2023: $799 · 2024: $349 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,837.32 | 2021-2025 | |
| Pfizer INC. | $383.40 | 2021-2025 | |
| Boston Scientific Corporation | $335.94 | 2021-2025 | Wavewriter Alpha Prime 16, General - Therapies, Infinion 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.84 | 2022-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $141.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.91 | 2022 | |
| Amgen INC. | $123.22 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $107.41 | 2022-2024 | Ztlido |
| Saluda Medical Americas, INC. | $103.32 | 2025 | Evoke |
| Collegium Pharmaceutical, INC. | $76.39 | 2021-2022 | |
| Protega Pharmaceutials INC | $60.86 | 2023-2025 | Roxybond |
| Lilly USA, LLC | $50.04 | 2021-2023 | Reyvow, Emgality |
| Almatica Pharma LLC | $49.76 | 2021-2022 | |
| Globus Medical, INC. | $49.24 | 2025 | Senza |
| Abbott Laboratories | $48.14 | 2021-2025 | Eterna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $47.56 | 2025 | Tirosint, Licart, Flector |
| Nevro Corp. | $36.30 | 2022-2023 | Senza |
| Forte Bio-Pharma LLC | $35.18 | 2024 | Prolate, Nalocet |
| Valinor Pharma, LLC | $33.52 | 2023-2024 | Movantik |
| Avanos Medical | $28.40 | 2024 | Standard Rf Disposables |
| Redhill Biopharma INC. | $28.06 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.78 | 2024 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $26.73 | 2021 | |
| Stimwave Technologies Incorporated | $20.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.55 | 2023 | Lyvispah |
| Nalu Medical, INC. | $18.40 | 2021 | |
| Biodelivery Sciences International, INC. | $15.72 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.06 | 2021 | |
| Horizon Therapeutics Plc | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azra Velic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.